This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events.
BackgroundAllergy to iodine contrast agents has long been a contraindication for balloon pulmonary angioplasty (BPA). Pulmonary artery pressure showed a significant decrease after performing BPA twice.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Angioplasty 
52 
Let's personalize your content